

DAFTAR PUSTAKA

- Borges, M., Afonso-Silva, M., Laires, P. A., Gouveia, M., Alarcão, J., Ascensão, R., & Costa, J. (2020). Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal. *Expert Review of Pharmacoeconomics and Outcomes Research*, 20(2), 199–205. <https://doi.org/10.1080/14737167.2019.1628642>
- Burnett, H., Earley, A., Voors, A. A., Senni, M., McMurray, J. J. V., Deschaseaux, C., & Cope, S. (2017). Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure with Reduced Ejection Fraction: A Network Meta-Analysis. *Circulation: Heart Failure*, 10(1). <https://doi.org/10.1161/CIRCHEARTFAILURE.116.003529>
- Chin, K. L., Zomer, E., Wang, B. H., & Liew, D. (2019). Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective. *Heart Lung and Circulation*, 29(9), 1310–1317. <https://doi.org/10.1016/j.hlc.2019.03.007>
- Docherty, K. F., Vaduganathan, M., Solomon, S. D., & McMurray, J. J. V. (2020). Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. *JACC: Heart Failure*, 8(10), 800–810. <https://doi.org/10.1016/j.jchf.2020.06.020>
- Drazner, M. H. (2011). The progression of hypertensive heart disease. *Circulation*, 123(3), 327–334. <https://doi.org/10.1161/CIRCULATIONAHA.108.845792>
- Franklin, S. S., Gustin, W., Wong, N. D., Larson, M. G., Weber, M. A., Kannel, W. B., & Levy, D. (1997). Hemodynamic Patterns of Age-Related Changes in Blood Pressure. *Circulation*, 96(1), 308–315. <https://doi.org/10.1161/01.CIR.96.1.308>
- Freund, D. A., & Dittus, R. S. (1992). Principles of Pharmacoeconomic Analysis of Drug Therapy. *Pharmacoeconomics*, 1(1), 20–29. <https://doi.org/10.2165/00019053-199201010-00006>
- Fröhlich, H., Henning, F., Täger, T., Schellberg, Di., Grundtvig, M., Goode, K., Corletto, A., Kazmi, S., Hole, T., Katus, H. A., Atar, D., Cleland, J. G. F., Agewall, S., Frankenstein, L., & Clark, A. L. (2018). Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: A propensity score-matched cohort study. *European Heart Journal - Cardiovascular Pharmacotherapy*, 4(2), 82–92. <https://doi.org/10.1093/ehjcvp/pvx013>
- Garg, R., & Yusuf, S. (1995). Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure Dr Yusuf has received monetary compensation for speaking engagements from several pharmaceutical companies, including some . *Jama*,

273, 1450–1456.

- Gary D. Hammer. (2018). Pathophysiology of Disease. In *Mc Graw Hill Wducation* (hal. 763–777).
- Gaziano, T. A., Fonarow, G. C., Claggett, B., Chan, W. W., Deschaseaux-Voinet, C., Turner, S. J., Rouleau, J. L., Zile, M. R., McMurray, J. J. V., & Solomon, S. D. (2016). Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. *JAMA Cardiology*, *1*(6), 666–672. <https://doi.org/10.1001/jamacardio.2016.1747>
- Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., ... Yancy, C. W. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. In *Circulation* (Vol. 145, Nomor 18). <https://doi.org/10.1161/CIR.0000000000001063>
- Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Stevenson, L. W., Jesup, M., Casey, D. E., Silver, M. A., Yancy, C. W., Smith, S. C., Jacobs, A. K., ... Tarkington, L. G. (2009). 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: Develop. *Circulation*, *119*(14). <https://doi.org/10.1161/CIRCULATIONAHA.109.192065>
- Jhund, P. S., & McMurray, J. J. V. (2016). The neprilysin pathway in heart failure: A review and guide on the use of sacubitril/valsartan. *Heart*, *102*(17), 1342–1347. <https://doi.org/10.1136/heartjnl-2014-306775>
- Jolicoeur, L. M., Jones-Grizzle, A. J., & Boyer, J. G. (1992). Guidelines for performing a pharmacoeconomic analysis. *American Journal of Hospital Pharmacy*, *49*(7), 1741–1747.
- Katritsis, D. G., Gersh, B. J., & Camm, A. J. (2016). Clinical Cardiology: Current Practice Guidelines. *Oxford University Press*, 378–379.
- Kazi, D., & Deswal, A. (2008). Role and Optimal Dosing of Angiotensin-Converting Enzyme Inhibitors in Heart Failure. *Cardiology Clinics*, *26*(1), 1–14. <https://doi.org/10.1016/j.ccl.2007.12.001>
- Kementerian Kesehatan Republik Indonesia. (2013). Pedoman Penerapan Kajian Farmakoekonomi. In *Kementerian Kesehatan RI*.
- Kementerian Kesehatan Republik Indonesia. (2014). Riset Kesehatan Dasar 2013. *Badan Penelitian dan Pengembangan Kesehatan*.

<https://doi.org/10.1126/science.127.3309.1275>

- Kementrian Kesehatan Republik Indonesia. (2019). Laporan Nasional Riskesdas 2018. In *Badan Penelitian dan Pengembangan Kesehatan* (hal. 674). http://labdata.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf
- Khder, Y., Shi, V., McMurray, J. J. V., & Lefkowitz, M. P. (2016). Sacubitril/Valsartan (LCZ696) in Heart Failure. *Springer International Publishing*. https://doi.org/10.1007/164_2016_77
- King, J. B., Shah, R. U., Bress, A. P., Nelson, R. E., & Bellows, B. K. (2016). Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. *JACC: Heart Failure*, 4(5), 392–402. <https://doi.org/10.1016/j.jchf.2016.02.007>
- Krittayaphong, R., & Permsuwan, U. (2018). Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand. *American Journal of Cardiovascular Drugs*, 18(5), 405–413. <https://doi.org/10.1007/s40256-018-0288-x>
- Lam, C. S. P., Arnott, C., Beale, A. L., Chandramouli, C., Hilfiker-Kleiner, D., Kaye, D. M., Ky, B., Santema, B. T., Sliwa, K., & Voors, A. A. (2019). Sex differences in heart failure. *European Heart Journal*, 40(47), 3859–3868c. <https://doi.org/10.1093/eurheartj/ehz835>
- Lee, C. Y. W., & Burnett, J. C. (2007). Natriuretic peptides and therapeutic applications. *Heart Failure Reviews*, 12(2), 131–142. <https://doi.org/10.1007/s10741-007-9016-3>
- Liang, L., Bin-Chia Wu, D., Aziz, M. I. A., Wong, R., Sim, D., Leong, K. T. G., Wei, Y. Q., Tan, D., & Ng, K. (2018). Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction. *Journal of Medical Economics*, 21(2), 174–181. <https://doi.org/10.1080/13696998.2017.1387119>
- Lilly, L. S. (2016). Pathophysiology of Heart Disease Fifth Edition. In *Havard Medical School*.
- Lillyblad, M. P. (2015). Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM. *Annals of Pharmacotherapy*, 49(11), 1237–1251. <https://doi.org/10.1177/1060028015593093>
- Maggioni, A. P. (2005). Review of the new ESC guidelines for the pharmacological management of chronic heart failure. *European Heart Journal, Supplement*, 7(J), 15–20. <https://doi.org/10.1093/eurheartj/sui058>

- McCormack, P. L. (2016). Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction. *Springer International Publishing*, 76(3), 387–396. <https://doi.org/10.1007/s40265-016-0544-9>
- McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Celutkiene, J., Chioncel, O., Cleland, J. G. F., Coats, A. J. S., Crespo-Leiro, M. G., Farmakis, D., Gilard, M., & Heymans, S. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *European Heart Journal*, 42(36), 3599–3726. <https://doi.org/10.1093/eurheartj/ehab368>
- McMurray, J. J. ., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., & Zile, M. R. (2014). Angiotensin-Nepriylsin Inhibition versus Enalapril in Heart Failure. *The New England Journal of Medicine*, 11(11), 993–1004. <https://doi.org/10.1056/NEJMoa1409077>
- McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., Gomez-Sanchez, M. A., Jaarsma, T., Køber, L., Lip, G. Y. H., Maggioni, A. Pietro, Parkhomenko, A., Pieske, B. M., Popescu, B. A., Rønnevik, P. K., Rutten, F. H., ... ESC Committee for Practice Guidelines. (2012). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. *European heart journal*, 33(14), 1787–1847. <https://doi.org/10.1093/eurheartj/ehs104>
- McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J., Shi, V. C., Solomon, S. D., Swedberg, K., & Zile, M. R. (2013). Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: Rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact. *European Journal of Heart Failure*, 15(9), 1062–1073. <https://doi.org/10.1093/eurjhf/hft052>
- McMurray, J. J. V., Trueman, D., Hancock, E., Cowie, M. R., Briggs, A., Taylor, M., Mumby-Croft, J., Woodcock, F., Lacey, M., Haroun, R., & Deschaseaux, C. (2018). Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. *Heart*, 104(12), 1006–1013. <https://doi.org/10.1136/heartjnl-2016-310661>
- Menteri Kesehatan Republik Indonesia. (2014). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 28 Tahun 2014 Tentang Pedoman Pelaksanaan Program Jaminan Kesehatan Nasional*.
- O'Rourke, M. (1995). Mechanical Principles in Arterial Disease. *Hypertension*, 26(1), 2–9.

- Perera, K., Ademi, Z., Liew, D., & Zomer, E. (2021). Sacubitril-valsartan versus enalapril for acute decompensated heart failure: A cost-effectiveness analysis. *European Journal of Preventive Cardiology*, 28(9), 966–972. <https://doi.org/10.1177/2047487319878953>
- PERKI. (2015). *Pedoman Tatalaksana Hipertensi pada Penyakit Kardiovaskular*. <https://doi.org/10.1103/PhysRevD.42.2413>
- PERKI. (2020). *Pedoman Tatalaksana Gagal Jantung*.
- Potter, L. R., Yoder, A. R., Flora, D. R., Antos, L. K., & Dickey, D. M. (2009). Natriuretic peptides: Their structures, receptors, physiologic functions and therapeutic applications. *Handbook of Experimental Pharmacology*, 191(191), 341–366. https://doi.org/10.1007/978-3-540-68964-5_15
- Safar, M. E. (1989). Pulse Pressure in Essential Hypertension: Clinical and Therapeutical Implications. *Journal of Hypertension*, 7, 769–776.
- Selvaraj, S., Claggett, B. L., Böhm, M., Anker, S. D., Vaduganathan, M., Zannad, F., Pieske, B., Lam, C. S. P., Anand, I. S., Shi, V. C., Lefkowitz, M. P., McMurray, J. J. V., & Solomon, S. D. (2020). Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. *Journal of the American College of Cardiology*, 75(14), 1644–1656. <https://doi.org/10.1016/j.jacc.2020.02.009>
- Sesso, H. D., Stampfer, M. J., Rosner, B., Hennekens, C. H., Gaziano, J. M., Manson, J. A. E., & Glynn, R. J. (2000). Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in men. *Hypertension*, 36(5), 801–807. <https://doi.org/10.1161/01.HYP.36.5.801>
- Sikiru, L., & Okoye, G. C. (2013). Effect of interval training programme on pulse pressure in the management of hypertension: A randomized controlled trial. *African Health Sciences*, 13(3), 571–578. <https://doi.org/10.4314/ahs.v13i3.7>
- Solomon, S. D., Rizkala, A. R., Gong, J., Wang, W., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., Van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Shi, V. C., ... McMurray, J. J. V. (2017). Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. *JACC: Heart Failure*, 5(7), 471–482. <https://doi.org/10.1016/j.jchf.2017.04.013>
- Solomon, S. D., Verma, A., Desai, A., Hassanein, A., Izzo, J., Oparil, S., Lacourciere, Y., Lee, J., Seifu, Y., Hilkert, R. J., Rocha, R., & Pitt, B. (2010). Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. *Hypertension (Dallas, Tex. : 1979)*, 55(2), 241–248. <https://doi.org/10.1161/HYPERTENSIONAHA.109.138529>

- Tate, R. B., Manfreda, J., Krahn, A. D., & Edward Cuddy, T. (1995). Tracking of blood pressure over a 40-year period in the university of manitoba follow-up study, 1948-1988. *American Journal of Epidemiology*, *142*(9), 946–954. <https://doi.org/10.1093/oxfordjournals.aje.a117742>
- Tomek, J., & Bub, G. (2017). Hypertension-induced remodelling: on the interactions of cardiac risk factors. *Journal of Physiology*, *595*(12), 4027–4036. <https://doi.org/10.1113/JP273043>
- Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E. (2019). Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. *New England Journal of Medicine*, *380*(6), 539–548. <https://doi.org/10.1056/nejmoa1812851>
- WHO. (2020). Noncommunicable Diseases Progress Monitor 2020. *Geneva*.
- Wright, J. T., Williamson, J. D., Whelton, P. K., Snyder, J. K., Sink, K. M., Rocco, M. V., Reboussin, D. M., Rahman, M., Oparil, S., Lewis, C. E., Kimmel, P. L., Johnson, K. C., Goff, D. C., Fine, L. J., Cutler, J. A., Cushman, W. C., Cheung, A. K., & Ambrosius, W. T. (2015). A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *New England Journal of Medicine*, *373*(22), 2103–2116. <https://doi.org/10.1056/nejmoa1511939>
- Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., Hollenberg, S. M., Lindenfeld, J. A., Masoudi, F. A., McBride, P. E., Peterson, P. N., Stevenson, L. W., & Westlake, C. (2017). 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer. *Circulation*, *136*(6), e137–e161. <https://doi.org/10.1161/CIR.0000000000000509>
- Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., Johnson, M. R., Kasper, E. K., Levy, W. C., Masoudi, F. A., McBride, P. E., McMurray, J. J. V., Mitchell, J. E., Peterson, P. N., Riegel, B., ... Wilkoff, B. L. (2013). 2013 ACCF/AHA guideline for the management of heart failure: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. *Circulation*, *128*(16), 240–327. <https://doi.org/10.1161/CIR.0b013e31829e8776>
- Zakiyah, N., Sinuraya, R. K., Kusuma, A. S. W., Suwantika, A. A., & Lestari, K. (2021). Cost-effectiveness analysis of sacubitril/valsartan compared to enalapril for heart failure patients in indonesia. *ClinicoEconomics and Outcomes Research*, *13*, 863–872. <https://doi.org/10.2147/CEOR.S322740>

Zanfina, A., Pfeil Alena, M., Elizabeth, H., David, T., Rola, H., Céline, D., & Matthias, S. (2017). Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction. *Swiss Medical Weekly*, *147*(45–46). <https://doi.org/10.4414/smw.2107.14533>